Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Melanoma 1Laryngeal Neoplasms 1Hematologic Neoplasms 1Glioma 1Genomic Instability 1Gastrointestinal Neoplasms 1Erdheim-Chester Disease 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Pemetrexed 6Cisplatin 4Carboplatin 4pembrolizumab 3pralsetinib 2osimertinib 2entinostat 2atezolizumab 2Paclitaxel 2130-nm albumin-bound paclitaxel 2trametinib 1siltuximab 1repotrectinib 1ficlatuzumab 1enzalutamide 1durvalumab 1dabrafenib 1cobimetinib 1cemiplimab 1Vemurafenib 1Taxes 1Nivolumab 1Injections 1Gemcitabine 1Gefitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Vemurafenib × Thoracic × Clear all
NCT05768178 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡